Skip to main content

AIM ImmunoTech Inc.

AIM
Exchange
NYSE
Industry
Biological Products, (No Diagnostic Substances)
SEC CIK
0000946644

In the last 90 days, AIM ImmunoTech Inc. insiders filed 4 open-market purchases and 0 sales; 18 institutions reported holding it in 13F filings for Q2 2026, worth $325.6K in total; no superinvestor holds it.

Q4 2022 vs. Q3 2022

How the institutions holding AIM ImmunoTech Inc. changed between Q3 2022 and Q4 2022.

All holders in Q4 2022All holders in Q3 2022

13F holders of AIM: Q3 2022 compared with Q4 2022
MeasureQ3 2022Of which not filed for Q4 2022Q4 2022Change
Holders38139+2
Shares5.78M2285.36M−415.0K (−7.2%)
Value$3.36M$133$1.67M−$1.69M (−50.3%)

1 institution that held it in Q3 2022 haven't filed for Q4 2022 yet. Not filing isn't selling, so the changes leave them out.

New holders (4)

Institutions that held AIM ImmunoTech Inc. at the end of Q4 2022 but not at the end of Q3 2022.

Institutions new to AIM in Q4 2022
InstitutionSharesValue% of portfolio
Citadel Advisors LLC70,257$21.9K0.00%
Two Sigma Securities, LLC14,431$4.50K0.00%
Proequities, Inc.500$1550.00%
Creative Capital Management Investments LLC200$00.00%

Sold out (2)

Institutions that held AIM ImmunoTech Inc. at the end of Q3 2022 and filed for Q4 2022 without it.

Institutions that sold out of AIM in Q4 2022
InstitutionShares, Q3 2022Value, Q3 2022
Captrust Financial Advisors20,000$12.0K
LPL Financial LLC15,982$9.00K

Not filed for Q4 2022 yet (1)

Institutions that held AIM ImmunoTech Inc. at the end of Q3 2022 and haven't filed a 13F for Q4 2022. Not filing isn't selling, so they aren't counted as sold out.

Institutions holding AIM in Q3 2022 that haven't filed for Q4 2022
InstitutionShares, Q3 2022Value, Q3 2022
American Portfolios Advisors228$133